Responsible entity: UNIPRO Sp
Ryan said that we do need better evidence around whether some individuals can maintain weight loss after coming off GLP-1s, but she thinks what Calibrate is doing is sharing the decision-making with the patient and trying to adapt to the environment where drugs may not always be available. Since Calibrate has come onto the market, results were published from a much larger, peer-reviewed study funded by the Ozempic manufacturer Novo Nordisk in 2022
Pharmacologic Considerations The choice of follow-up therapy differs significantly
Pricing & Availability Pricing & Availability Specifications Pricing & Availability Specifications Pricing & Availability Pricing & Availability Pricing & Availability Specifications Pricing & Availability Pricing & Availability Specifications Pricing & Availability Specifications
Peel A, Saini A, Deluao JC, McPherson NO
While side effects from semaglutide are rare, they can still happen